GlassScriptPhysician profile
Fredicia L Stembridge
NPI 1134467301
$1,814.93
in general payments reported to CMS, 2019-2025
27 companies · $19.79 in 2025
The $19.79 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $393 · 2022: $247 · 2023: $799 · 2024: $356 · 2025: $19.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $230.83 | 2021-2023 | Tyvaso, Orenitram, Remodulin |
| Astrazeneca Pharmaceuticals LP | $198.67 | 2021-2025 | Fasenra, Tagrisso, Breztri |
| Jazz Pharmaceuticals INC. | $167.63 | 2021-2024 | |
| Grifols USA, LLC | $140.19 | 2023-2024 | Prolastin-C Liquid, Xembify |
| Insmed, INC. | $123.71 | 2021-2023 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $105.41 | 2022-2023 | Opsumit, Uptravi |
| Harmony Biosciences LLC | $98.69 | 2023 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.55 | 2021-2023 | Ofev |
| Janssen Pharmaceuticals, INC | $75.72 | 2021 | |
| Inspire Medical Systems, INC. | $72.87 | 2023-2024 | Inspire |
| Glaxosmithkline, LLC. | $64.25 | 2021-2024 | Arexvy, Trelegy Ellipta, Nucala |
| Novartis Pharmaceuticals Corporation | $51.70 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.21 | 2022-2023 | Glassia |
| Zoll Respicardia, INC. | $38.93 | 2024 | Remede System |
| Bayer Healthcare Pharmaceuticals INC. | $34.71 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $33.32 | 2023 | Yupelri |
| Pfizer INC. | $31.59 | 2021 | |
| Johnson & Johnson Health Care Systems INC. | $29.73 | 2023 | Opsumit |
| Resmed Corp | $29.39 | 2022-2023 | |
| Csl Behring | $27.95 | 2024 | Hizentra |
| Vanda Pharmaceuticals INC. | $26.91 | 2022 | |
| Merck Sharp & Dohme LLC | $20.37 | 2023 | Belsomra |
| Ani Pharmaceuticals, INC. | $19.87 | 2024 | Purified Cortrophin Gel |
| Idorsia Pharmaceuticals US INC | $18.64 | 2023 | Quviviq |
| Gilead Sciences, INC. | $15.46 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.39 | 2022 | |
| Inogen, INC. | $2.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredicia Stembridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.